Table 2 Anti-PD-1/PD-L1 combinational therapy and applications

Pembrolizumab

Pemetrexed; carboplatin; paclitaxel; gemcitabine; cisplatin; 5-fuorouracil; trastuzumab; radiotherapy; Axitinib; Lenvatinib;

PF-05082566

Solid tumors; NSCLC; SCLC; TNBC; GC;

[170,171,172,173]

Nivolumab

5-fuorouracil; oxaliplatin; capecitabine; oxaliplatin; ipilimumab; radiotherapy

NSCLC; SCLC; GC; colorectal cancer;

Esophageal adenocarcinoma

[174, 175]

Camrelizumab

Carboplatin; pemetrexed; gemcitabine; cisplatin; apatinib

Nasopharyngeal carcinoma; NSCLC; GC; HCC; SCLC; esophageal squamous cell carcinoma

[176, 177]

Tislelizumab

Paclitaxel; carboplatin; platinum; pemetrexed; pamiparib

NSCLC

[178,179,180]

Atezolizumab

Bevacizumab; paclitaxel; carboplatin; etoposide; KY1044; alectinib; ipatasertib

NSCLC; SCLC; TNBC; HCC

[181,182,183]

Durvalumab

Etoposide; carboplatin; cisplatin; axitinib; radiotherapy

NSCLC; SCLC; RCC

[184,185,186,187]